Pulmonary Arterial Hypertension (PAH)-Market Insight, Epidemiology and Market Forecast-2027
- March 2018
- 100 pages
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm
The DelveInsight Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the Pulmonary Arterial Hypertension (PAH) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension (PAH) in the US, Europe, and Japan.
Pulmonary Arterial Hypertension (PAH) Epidemiology
The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, sex-specific prevalent cases, and sub-type specific prevalent cases) scenario of Pulmonary Arterial Hypertension (PAH)in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total number of prevalent population of Pulmonary Arterial Hypertension (PAH) was found to be more than 70,000 in 7MM, in the year 2016. Women account for 70% of the total prevalent cases.
Pulmonary Arterial Hypertension (PAH) Drug Chapters
This segment of the Pulmonary Arterial Hypertension (PAH) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Therapeutic market of PAH is dominated with the use of endothelin receptor antagonists, prostanoids, calcium channel blockers, phosphodiesterase inhibitors and Soluble Guanylate Cyclase (sGC) stimulators. Detailed chapters of all these therapies, along with the upcoming therapies such as Aurora-GT ((United Therapeutics Corp.), Tysuberprost (United Therapeutics Corp.) and Macitentan (Actelion Pharmaceuticals Ltd) have been covered in the report.
Pulmonary Arterial Hypertension (PAH) Market Outlook
The Pulmonary Arterial Hypertension (PAH) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be USD 5.13 Billion in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.
Pulmonary Arterial Hypertension (PAH) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Pulmonary Arterial Hypertension (PAH) Report Insights
Market Size and Trends
Impact of upcoming Therapies
Pulmonary Arterial Hypertension (PAH) Report Key Strengths
10 Year Forecast
Highly Analyzed Market
Key Cross Competition
Pulmonary Arterial Hypertension (PAH) Report Assessment
Current Treatment Practices
Detailed Pipeline Product Profiles
Market Drivers and Barriers
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Pulmonary Arterial Hypertension (PAH) market
Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) market
To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market.
Have query on this report?Make an Enquiry
2. Pulmonary Arterial Hypertension Market Overview at a Glance
2.1. Global Market Share Distribution of Pulmonary Arterial Hypertension in 2016
2.2. Global Market Share Distribution of Pulmonary Arterial Hypertension in 2027
3. Pulmonary Arterial Hypertension (PAH): Overview
Table 2: Prevalent Population of PAH in United States (2016-2027)
Table 3: Sub-type Specific Population of PAH in United States (2016-2027)
Table 4: Gender Specific Population of PAH in United States (2016-2027)
Table 5: Prevalent Population of PAH in Germany (2016-2027)
Table 6: Sub-type Specific Population of PAH in Germany (2016-2027)
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017